Helen May Brady

US Patent:

20030054332, Mar 20, 2003

Filed:

May 10, 2001

Appl. No.:

09/853544

Inventors:

Miguel Barbosa - Claremont CA, US
Helen Brady - San Diego CA, US
Kyle Chan - San Diego CA, US
Jose Pardinas - Bothell WA, US

International Classification:

C12Q001/00
C12Q001/68
C07H021/04
C12N005/06

US Classification:

435/004000, 435/006000, 435/325000, 536/023500

Abstract:

Methods are provided for evaluating estrogenic and antiestrogenic effects of candidate therapeutic agents. Such methods are generally based on assays to detect modulation of estrogen-regulated marker expression in one or more specific cell types. Agents identified using such methods may be used, for example, in the prevention and treatmnt of diseases such as osteoporosis, cardiovascular disease and cancer. In addition, the gene discovery approaches discussed have identified a unique gene profile for estrogen regulation in vascular endothelial cells. This gene profile will allow characterization of the effects of potential SERMs in the cardiovascular system. This gene profile and the assays established with these genes will enable more extensive evaluation of tissue specific properties of SERM compounds and provide a better understanding of cardiovascular effects of SERMs.

US Patent:

20050064462, Mar 24, 2005

Filed:

Jun 16, 2004

Appl. No.:

10/870387

Inventors:

Bernd Stein - San Diego CA, US
Helen Brady - San Diego CA, US
Dan Zhu - San Diego CA, US

International Classification:

C12Q001/68
G01N033/53
G01N033/567
A61K031/56
A61K031/445
A61K031/138

US Classification:

435006000, 435007200, 514182000, 514319000, 514651000

Abstract:

The present invention provides methods, compositions, and kits, for determining the effects of one or more candidate compounds on hot flash symptoms. In certain aspects, the methods, compositions, and kits can be used to identify compounds that decrease the incidence of hot flash symptoms. In other aspects, the methods, compositions, and kits can be used to determine whether candidate compounds increase the incidence of undesirable hot flash symptoms when administered to a subject.

US Patent:

20050143420, Jun 30, 2005

Filed:

Dec 2, 2004

Appl. No.:

11/004736

Inventors:

Laure Moutouh-de Parseval - San Diego CA, US
Kyle Chan - San Diego CA, US
Helen Brady - San Diego CA, US

International Classification:

A61K031/454

US Classification:

514323000

Abstract:

The present invention is directed to the use of immunomodulatory compounds, particularly members of the class of compounds known as IMiDs™, and more specifically the compounds 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione, to induce the expression of fetal hemoglobin genes, genes essential for erythropoiesis, and genes encoding alpha hemoglobin stabilizing protein, within a population of CD34cells. These compounds are used to treat hemoglobinopathies such as sickle cell anemia or β-thalassemia, or anemias caused by disease, surgery, accident, or the introduction or ingestion of toxins, poisons or drugs.

US Patent:

20070066512, Mar 22, 2007

Filed:

Sep 11, 2006

Appl. No.:

11/519732

Inventors:

Dominique Verhelle - San Diego CA, US
Kyle Chan - San Diego CA, US
Helen Brady - San Diego CA, US

International Classification:

A61K 38/22
A61K 38/28
A61K 38/12
A61K 38/09
A61K 31/573
A61K 31/7034
A61K 31/545
A61K 31/55
A61K 31/473

US Classification:

514002000, 514003000, 514179000, 514015000, 514035000, 514192000, 514200000, 514171000, 514269000, 514284000, 514217000, 514649000, 514009000

Abstract:

Methods of treating, preventing and/or managing disorders associated with low plasma leptin levels are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent.

US Patent:

20080051431, Feb 28, 2008

Filed:

May 24, 2007

Appl. No.:

11/807076

Inventors:

Dominique Verhelle - San Diego CA, US
Kyle Chan - San Diego CA, US
Laura Corral - La Jolla CA, US
Laure Moutouh de Parseval - Summit NJ, US
Helen Brady - San Diego CA, US

International Classification:

A61K 31/445
A61P 35/00

US Classification:

514323000

Abstract:

Provided herein are compositions comprising one or more immunomodulatory compounds and valproic acid, hydroxyurea or trichostatin A, methods for their use in CD34+ hematopoietic stem cell expansion in vitro and in vivo for bone marrow reconstitution and bone marrow transplantation, increasing fetal hemoglobin expression, and methods for treating, preventing and/or managing cancer, tumors and hematological diseases and disorders.

US Patent:

20090176237, Jul 9, 2009

Filed:

Dec 19, 2008

Appl. No.:

12/340472

Inventors:

Gregory D. Ferguson - San Diego CA, US
Helen Brady - San Diego CA, US
Kyle Chan - San Diego CA, US
Normand R. Richard - Ramona CA, US

International Classification:

C12Q 1/68
C12M 1/00
C40B 40/08

US Classification:

435 6, 4352872, 506 17

Abstract:

Methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample are disclosed. Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound.

US Patent:

20090232796, Sep 17, 2009

Filed:

Feb 20, 2009

Appl. No.:

12/390220

Inventors:

Laura G. Corral - San Diego CA, US
Helen Brady - San Diego CA, US
Kyle Chan - San Diego CA, US

International Classification:

A61K 39/395
A61K 31/454

US Classification:

4241301, 514323

Abstract:

Provided herein relates to the field of cancer and its treatment by administering immunomodulatory compounds in combination with other compounds. In particular, a combination of an immunomodulatory compound and an anti-CD40 antibody and/or a CD40 ligand is provided.

US Patent:

20090317385, Dec 24, 2009

Filed:

Jan 29, 2009

Appl. No.:

12/362411

Inventors:

Helen A. Brady - San Diego CA, US
Kyle Chan - San Diego CA, US

International Classification:

A61K 31/454
A61P 7/00
A61K 31/519
A61K 33/26
A61K 38/22
A61K 39/395
A61P 37/00

US Classification:

4241331, 514323, 514249, 424646, 514 12, 4241301

Abstract:

Provided herein are methods of treating, preventing or managing disorders associated with low CD59 levels. The methods encompass the administration of an immunomodulatory compound provided herein, such as 3-(4-amino--oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline. Further described are methods of treatment using the immunomodulatory compounds in combination with other therapeutic agents or therapies. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.